Analysts Set CeriBell (NASDAQ:CBLL) Price Target at $32.50

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) have been assigned an average recommendation of "Buy" from the seven brokerages that are presently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $32.50.

A number of equities analysts have recently issued reports on the company. LADENBURG THALM/SH SH assumed coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th.

Insider Activity at CeriBell

In other news, CEO Xingjuan Chao sold 3,372 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $15.03, for a total transaction of $50,681.16. Following the completion of the sale, the chief executive officer now owns 743,079 shares of the company's stock, valued at approximately $11,168,477.37. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 49,700 shares of company stock worth $796,434 in the last ninety days. 20.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently added to or reduced their stakes in CBLL. Quantbot Technologies LP bought a new position in shares of CeriBell during the first quarter valued at about $175,000. Lord Abbett & CO. LLC increased its holdings in CeriBell by 7.9% during the 1st quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after purchasing an additional 23,451 shares during the period. Nuveen LLC bought a new position in CeriBell during the 1st quarter valued at approximately $311,000. Swiss National Bank purchased a new stake in CeriBell in the 1st quarter worth approximately $467,000. Finally, CenterBook Partners LP bought a new position in shares of CeriBell during the first quarter valued at approximately $3,531,000.

CeriBell Trading Down 0.6%

Shares of CBLL stock traded down $0.10 on Friday, reaching $17.18. The company's stock had a trading volume of 306,181 shares, compared to its average volume of 279,841. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75. The stock's 50 day simple moving average is $17.00 and its 200-day simple moving average is $21.95.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. On average, equities research analysts anticipate that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.